Tyngsborough, MA, United States of America

Robert B Nicewonger

This inventor holds 11 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Arqule, Inc., Jasco Pharmaceuticals, LLC. Active years: 2012-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert B Nicewonger. Retrieved from https://idiyas.com/inventor/robert-b-nicewonger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 90.9

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 6.1

ph-index = 6

Forward Citations = 84(Granted Patents)

Company Filing History:

Jasco Pharmaceuticals, LLC

patents

Years Active: 2012-2015

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9157077 - Aminopyrimidine kinase inhibitors (2015-10-13),

2. 9073903 - Imidazole-2,4-dione inhibitors of casein kinase 1 (2015-07-07),

3. 8962619 - Substituted imidazopyridinyl-aminopyridine compounds (2015-02-24),

4. 8815854 - Substituted imidazopyridinyl compounds (2014-08-26),

5. 8609688 - Substituted imidazopyridinyl-aminopyridine compounds (2013-12-17),

6. 8563539 - Aminopyrimidine kinase inhibitors (2013-10-22),

7. 8501770 - Substituted imidazopyridinyl-aminopyridine compounds (2013-08-06),

8. 8497276 - Substituted indolo-piperidine compounds (2013-07-30),

9. 8343961 - Substituted heterocyclic compounds (2013-01-01),

10. 8273754 - Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds (2012-09-25),

11. 8173808 - Substituted naphthalenyl-pyrimidine compounds (2012-05-08),

Title: Innovator Robert B. Nicewonger: A Pioneer in Pharmaceutical Research

Introduction

Robert B. Nicewonger, an accomplished inventor based in Tyngsboro, Massachusetts, holds an impressive portfolio of 11 patents. His contributions to the field of pharmaceutical research, particularly in the development of kinase inhibitors, have made significant strides in therapeutic advancements.

Latest Patents

Among Robert's latest patents are innovative compounds that function as aminopyrimidine kinase inhibitors. These compounds, along with their pharmaceutical compositions, are designed to modulate various pathways, including the casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), and the TGFβ, Wnt, JAK/STAT, and mTOR pathways. Such inventions are paramount for treating or preventing conditions linked to abnormal physiological activity within these pathways. Additionally, Robert has patented imidazole-2,4-dione inhibitors of casein kinase 1. Similar to his aminopyrimidine compounds, these inventions also target significant biological pathways and have potential therapeutic implications.

Career Highlights

Robert B. Nicewonger has worked with notable companies in the pharmaceutical sector, including Arqule, Inc. and Jasco Pharmaceuticals, LLC. His work at these organizations has provided him with invaluable experience and has propelled his research in the pharmaceutical industry. With a focus on proteins and pathways crucial to cellular function, Robert has pioneered methods that contribute to the understanding and treatment of various diseases.

Collaborations

Throughout his career, Robert has collaborated with talented professionals in the field, including colleagues such as Mark Anthony Ashwell and Jason Hill. Their collective expertise and teamwork have undoubtedly enriched the projects they undertook, advancing innovative solutions in pharmacology.

Conclusion

Robert B. Nicewonger exemplifies the spirit of innovation in the pharmaceutical industry through his substantial contributions and numerous patents. By focusing on critical biological pathways and developing targeted inhibitors, his work continues to influence therapeutic strategies and open doors for future research in the field.

Profile summary based on public USPTO records.